HomeCompareVMSSF vs ABBV

VMSSF vs ABBV: Dividend Comparison 2026

VMSSF yields 6349.21% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMSSF wins by $638035556987769.63M in total portfolio value
10 years
VMSSF
VMSSF
● Live price
6349.21%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$638035556987769.75M
Annual income
$618,861,594,776,093,500,000.00
Full VMSSF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VMSSF vs ABBV

📍 VMSSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMSSFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMSSF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMSSF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMSSF
Annual income on $10K today (after 15% tax)
$539,682.54/yr
After 10yr DRIP, annual income (after tax)
$526,032,355,559,679,400,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VMSSF beats the other by $526,032,355,559,679,400,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMSSF + ABBV for your $10,000?

VMSSF: 50%ABBV: 50%
100% ABBV50/50100% VMSSF
Portfolio after 10yr
$319017778493884.94M
Annual income
$309,430,797,388,046,700,000.00/yr
Blended yield
96.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VMSSF
No analyst data
Altman Z
-2.6
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMSSF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMSSFABBV
Forward yield6349.21%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$638035556987769.75M$102.3K
Annual income after 10y$618,861,594,776,093,500,000.00$24,771.77
Total dividends collected$636747364282948.88M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VMSSF vs ABBV ($10,000, DRIP)

YearVMSSF PortfolioVMSSF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$645,621$634,920.63$11,550$430.00+$634.1KVMSSF
2$39,000,895$38,310,080.70$13,472$627.96+$38.99MVMSSF
3$2,204,581,239$2,162,850,281.50$15,906$926.08+$2204.57MVMSSF
4$116,618,900,958$114,259,999,032.18$19,071$1,382.55+$116618.88MVMSSF
5$5,773,544,203,387$5,648,761,979,362.42$23,302$2,095.81+$5773544.18MVMSSF
6$267,540,055,704,175$261,362,363,406,550.72$29,150$3,237.93+$267540055.68MVMSSF
7$11,605,203,458,201,158$11,318,935,598,597,690.00$37,536$5,121.41+$11605203458.16MVMSSF
8$471,283,438,056,651,970$458,865,870,356,376,700.00$50,079$8,338.38+$471283438056.60MVMSSF
9$17,919,590,852,033,930,000$17,415,317,573,313,310,000.00$69,753$14,065.80+$17919590852033.86MVMSSF
10$638,035,556,987,769,700,000$618,861,594,776,093,500,000.00$102,337$24,771.77+$638035556987769.63MVMSSF

VMSSF vs ABBV: Complete Analysis 2026

VMSSFStock

Vortex Metals Inc. engages in the exploration of copper-gold properties in Mexico. It holds 100% interests in two copper-gold volcanogenic massive sulfide (VMS) properties, including the Riqueza Marina copper-gold project covering an area of 15,840 hectares; and the Zaachila copper-gold project in covering an area of 3,264 hectares located in the state of Oaxaca. The company is based in Toronto, Canada.

Full VMSSF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VMSSF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMSSF vs SCHDVMSSF vs JEPIVMSSF vs OVMSSF vs KOVMSSF vs MAINVMSSF vs JNJVMSSF vs MRKVMSSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.